The Cytogenefics Core has been approved as an established Shared Resource of DF/HCC since it's founding. Charies Lee has directed the facility since 2006, after serving as its Assistant Director for six years. Cytogenetic studies can provide insight into regions of the genome that are pathogenetic in various neoplasms leading to an understanding ofthe molecular pathways participating in the biology of cancer. An invaluable function of the Cytogenetics Core is access to consultation for experimental design and data interpretation with the Core Directors. Consultation provides the investigator with guidance and advice regarding the best approach for the goal(s) of a specific study. Services of the Core are primarily focused on human and mouse cytogenetics and include: 1) conventional karyotyping of fissue specimens and cell lines, 2) fluorescence in situ hybridization (FISH) for metaphase and interphase preparations, and 3) comparative genomic hybridization (CGH) on microarrays. Director: Charies Lee, PhD(MWH) Category: 1.15 (Cytogenetics) Management: Joint (Cancer Center and Institutional).

Public Health Relevance

The mission of the Cytogenetics Core is to provide state-of-the-art cytogenetics services to DF/HCC scientists to facilitate investigations of the pathogenesis and pathobiology of neoplasia. Cytogenetic studies may also be important in establishing a diagnosis for correlation with clinical outcome. Cytogenetics is a fundamental adjunct to a variety of investigations underway, including basic and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$182,287
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications